Researchers engineered a nanobody-conjugated liposome (A5-LNP-DOX) that targets CD155 and delivers doxorubicin directly to ...

A new treatment option, Datroway (datopotamab deruxtecan or Dato-DXd), is now available for people with non-small cell lung ...

Bizengri for Some with NSCLC, Pancreatic Adenocarcinoma. The FDA has approved Bizengri (zenocutuzumab-zbco), the first systemic therapy for patients with advanced, unresectable, or metastatic ...

A new study by researchers at the Icahn School of Medicine at Mount Sinai, Memorial Sloan Kettering Cancer Center, and ...

A new study by researchers at the Icahn School of Medicine at Mount Sinai, Memorial Sloan Kettering Cancer Center, and ...

As cancer cases have increased worldwide, the disease has become more complex, presenting challenges to scientific advances in diagnosis and treatment. In this context, artificial intelligence (AI) ...

There are three main subtypes of NSCLC: adenocarcinoma, squamous cell carcinoma, and large cell carcinoma. Each subtype starts in different lung cells, but treatment and prognosis for each are ...

While cancer-associated fibroblasts (CAFs) significantly influence tumor progression, their temporal dynamics remain poorly understood. We investigated time-dependent interactions between non-small ...

Nearly a quarter of all newly diagnosed patients with advanced lung cancer are not given a test that could improve their chances for long-term survival and reduce their side effects.